Heart Failure: Types, Stages, and What It Means

Heart failure is one of the most prevalent cardiovascular diagnoses in the United States, affecting an estimated 6.7 million adults according to the American Heart Association's 2023 Heart Disease and Stroke Statistics Update. The condition is not a single disease but a clinical syndrome with distinct subtypes, measurable stages, and a defined trajectory that shapes both monitoring and management decisions. Understanding its classification structure is foundational to interpreting why different patients follow different care pathways. This page covers the major types, the two dominant staging systems, common clinical presentations, and the key boundaries that distinguish one category from another.

Definition and Scope

Heart failure is defined by the American College of Cardiology (ACC) and the American Heart Association (AHA) as a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection of blood. The heart does not stop beating; instead, it loses the capacity to meet the body's circulatory demands at normal filling pressures.

The scope of the condition is broad. Heart failure serves as a downstream consequence of coronary artery disease, hypertension, cardiomyopathy, heart valve disease, and congenital abnormalities, among other causes. It is also the leading cause of hospitalization in adults over age 65 in the United States (Centers for Medicare & Medicaid Services, CMS Hospital Quality data).

The primary regulatory and clinical framework governing heart failure classification in the US comes from the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure, published in the Journal of the American College of Cardiology. This guideline replaced and extended earlier versions and introduced updated staging terminology that supersedes older informal descriptors.

How It Works

The Two Major Types by Ejection Fraction

The most clinically decisive classification divides heart failure based on left ventricular ejection fraction (LVEF) — the percentage of blood pumped out of the left ventricle with each contraction. An echocardiogram is the standard tool for measuring LVEF.

The 2022 ACC/AHA/HFSA guideline defines three primary ejection fraction categories:

Heart Failure with Reduced Ejection Fraction (HFrEF) — LVEF of 40% or below. The ventricle contracts weakly. This subtype has the most established evidence base for pharmacological intervention, including angiotensin-converting enzyme inhibitors, beta-blockers, and SGLT2 inhibitors.
Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) — LVEF between 41% and 49%. Previously called the "gray zone," this category was formally defined in the 2022 guideline to acknowledge a distinct intermediate population.
Heart Failure with Preserved Ejection Fraction (HFpEF) — LVEF of 50% or greater. The ventricle contracts normally but is abnormally stiff, impairing filling. HFpEF accounts for roughly 50% of all heart failure cases (AHA, 2023 Statistics Update) and is more common in older adults, women, and individuals with obesity or diabetes.

The Two Dominant Staging Systems

ACC/AHA Staging (A–D): This four-stage framework, established in 2001 and updated through subsequent guidelines, tracks progression from risk to refractory disease:

Stage A: At risk for heart failure; no structural disease, no symptoms.
Stage B: Structural heart disease present; no current or prior symptoms.
Stage C: Structural disease with prior or current symptoms.
Stage D: Advanced heart failure refractory to standard treatment.

NYHA Functional Classification (I–IV): Developed by the New York Heart Association, this system classifies symptom severity during physical activity:

Class I: No limitation; ordinary activity does not cause symptoms.
Class II: Slight limitation; comfortable at rest, but ordinary activity causes fatigue or dyspnea.
Class III: Marked limitation; comfortable at rest, but less-than-ordinary activity causes symptoms.
Class IV: Symptoms at rest; unable to carry out physical activity without discomfort.

The two systems serve different functions. ACC/AHA staging reflects disease progression and is largely irreversible — a patient moves forward through stages, not backward. NYHA class reflects functional status and can improve with treatment. Clinicians often document both in tandem.

Common Scenarios

Heart failure presents across a spectrum. Three patterns appear most frequently in clinical settings:

Acute decompensated heart failure (ADHF): A sudden worsening of symptoms — typically fluid accumulation, severe dyspnea, and reduced oxygen saturation — requiring urgent or emergency evaluation. ADHF accounts for over 1 million hospitalizations annually in the US (Agency for Healthcare Research and Quality, HCUP data).

Chronic stable heart failure: Persistent structural impairment with symptoms that remain at a steady baseline over weeks to months. Patients in NYHA Class II or III may sustain this state for years with consistent medication and monitoring through programs such as cardiac rehabilitation.

New-onset heart failure: First presentation of symptoms in a patient without prior diagnosis. This scenario requires prompt workup to identify reversible causes, including ischemia, arrhythmia, thyroid dysfunction, or valvular disease.

Monitoring tools used across these scenarios include electrocardiograms, blood tests for biomarkers such as BNP and NT-proBNP, and serial echocardiography. For patients with advanced HFrEF, device therapies such as implantable cardioverter-defibrillators and cardiac resynchronization therapy via pacemakers carry Class I recommendations in the 2022 ACC/AHA/HFSA guideline.

Decision Boundaries

The classification boundaries in heart failure are not arbitrary thresholds — each carries clinical and regulatory weight.

The 40% LVEF cutoff separates HFrEF from HFmrEF and determines eligibility for specific evidence-based pharmacological regimens. Drug trials that established mortality benefit from sacubitril/valsartan, carvedilol, and dapagliflozin enrolled populations defined by this threshold.

The Stage A/B boundary is a preventive medicine frontier. Stage A patients carry risk factors but have no structural pathology — this is the domain of preventive cardiology and primary prevention strategy. Stage B patients require structural surveillance even in the absence of symptoms.

The Stage C/D boundary triggers consideration of advanced therapies. Stage D patients who remain symptomatic at rest despite optimal guideline-directed medical therapy may be evaluated for left ventricular assist devices or heart transplantation. The regulatory-context-for-cardiology page covers how CMS coverage determinations and FDA device approvals intersect with these clinical thresholds.

HFpEF vs. HFrEF as a treatment boundary: These two subtypes respond differently to pharmacotherapy. Treatments proven to reduce mortality in HFrEF — particularly beta-blockers and ACE inhibitors — have not demonstrated equivalent mortality benefit in HFpEF, a distinction the 2022 guideline addresses explicitly.

The cardiology authority reference index provides navigational context across the full range of cardiovascular conditions covered within this resource.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)